Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tumor Cell Detection System for Prostate Cancer

Key clinical point: A circulating tumor cell (CTC) detection system for prostate cancer (PCa) was developed on the basis of epithelial cell adhesion molecule (EpCAM)-targeted immunomagnetic separation and CK-FITC and SATB-1-APC immunofluorescence assay, and the recovery rate of tumor cells in PBS and simulated whole blood by this system was detected.

Major finding: The expression of SATB-1 in CTCs in the blood samples of PCa patients with different clinical characteristics and in the urine samples of a few PCa patients with bone metastases were different, and the detection sensitivity of peripheral blood was higher than that of urine.

Study details: Researchers isolated, identified, and counted SATB-1 positive CTCs in the peripheral blood and urine samples of 60 tumor-bearing nude mice, 5 healthy volunteers and 13 PCa patients.

Citation:

Cao C, et al. J Biomed Nanotechnol. 2019 Mar 1;15(3):612-620. doi: 10.1166/jbn.2019.2706.